Informations générales (source: ClinicalTrials.gov)
A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation, Confirmation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of TH9619 in Subjects With Advanced Solid Tumors
Interventional
Phase 1/Phase 2
One-carbon Therapeutics AB (Voir sur ClinicalTrials)
août 2025
décembre 2026
02 février 2026
This is a first in human, multi-center, open-label, dosage escalation study to determine
the recommended dose range of TH9619 in subjects with advanced cancer.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Antoine HOLLEBECQUE | 17/07/2026 10:35:05 | Contacter | ||
Critères
Tous
- Must have given written informed consent
- Histopathologically confirmed advanced cancer (colorectal cancer, head and neck
squamous cell cancer, non-small cell lung cancer and gastric cancer (including
gastroesophageal junction cancer))
- Prior treatment with at least one line of cytotoxic systemic therapy for
metastatic/unresectable cancer
- Adult patients (≥18 years of age)
- Must be willing to comply with study procedures
Exclusion Criteria:
• History or presence of any clinically significant disorders as judged by the
Investigator.